Cogent Biosciences (COGT) Other Non-Current Liabilities (2020 - 2026)

Cogent Biosciences (COGT) has reported Other Non-Current Liabilities for 5 consecutive years, with $62000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 1140.0% year-over-year to $62000.0; the TTM figure through Mar 2026 stood at $62000.0 (up 1140.0% YoY), while the FY2025 annual figure was $33000.0, changed N/A from the prior year.
• Other Non-Current Liabilities advanced to $62000.0 in Q1 2026 per COGT's latest filing, from $33000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $2.4 million in Q3 2025 and bottomed at $5000.0 in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $1.1 million across 3 years, with a median of $881000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 44.44% — and 2026, when it jumped 1140.0%.
• Cogent Biosciences' Other Non-Current Liabilities stood at $1.7 million in 2022, then sank by 98.06% to $33000.0 in 2025, then jumped by 87.88% to $62000.0 in 2026.
• Business Quant data shows COGT's Other Non-Current Liabilities at $62000.0 in Q1 2026, $33000.0 in Q4 2025, and $2.4 million in Q3 2025.